Betaglucin soluble gel 0.2% — Competitive Intelligence Brief

Betaglucin soluble gel 0.2% (Betaglucin soluble gel 0.2%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Immunology / Oncology.

phase 3 Immunomodulator Complement receptor 3 (CR3), Dectin-1 Immunology / Oncology Small molecule

Target snapshot

Betaglucin soluble gel 0.2% (Betaglucin soluble gel 0.2%) — Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri. Betaglucin is a beta-glucan immunomodulator that enhances innate immune responses by activating pattern recognition receptors on immune cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Betaglucin soluble gel 0.2% TARGET	Betaglucin soluble gel 0.2%	Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri	phase 3	Immunomodulator	Complement receptor 3 (CR3), Dectin-1
Ganoderma lucidum	Ganoderma lucidum	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Herbal/botanical immunomodulator
herbal immunomodulator	herbal immunomodulator	Tatyasaheb Kore Dental College	marketed	Herbal immunomodulator
VRD for first-cycle induction therapy	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
bee venom	bee venom	Assistance Publique - Hôpitaux de Paris	marketed	Natural product immunomodulator
ferrous gluconate with lactoferrin	ferrous gluconate with lactoferrin	Ain Shams University	marketed	Iron supplement with immunomodulatory adjuvant
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

1. Actavis Mid-Atlantic LLC · 1 drug in this class
2. Active Biotech AB · 1 drug in this class
3. Air Force Military Medical University, China · 1 drug in this class
4. Astellas Pharma Inc · 1 drug in this class
5. Bayer · 1 drug in this class
6. Beijing Children's Hospital · 1 drug in this class
7. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
8. Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
9. Chang Gung Memorial Hospital · 1 drug in this class
10. ALK-Abelló A/S · 1 drug in this class